Literature DB >> 17400533

Reactivation of tuberculosis by tumor necrosis factor neutralization.

Muazzam Jacobs1, Arina Samarina, Sergei Grivennikov, Tania Botha, Nasiema Allie, Cecile Fremond, Dieudonnée Togbe, Virginie Vasseur, Stephanie Rose, Francois Erard, Analbery Monteiro, Valerie Quesniaux, Bernhard Ryffel.   

Abstract

Tumor necrosis factor (TNF) is required in the control of infection with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis. TNF is essential and non-redundant for forming microbiocidal granulomas, and cannot be replaced by other members of the TNF family. We established a model of latent Mtb infection in mice, allowing investigation of the reactivation of latent Mtb as observed in patients receiving TNF-neutralizing therapy used in rheumatoid arthritis and Crohn's disease. Antibody neutralization of TNF is able to reactivate clinically silent Mtb infection. Using mutant mice expressing solely membrane, but not soluble TNF, we demonstrated that membrane TNF is sufficient to control acute Mtb infection. Therefore, we hypothesize that TNF-neutralizing therapy, sparing membrane TNF, may have an advantage as compared to complete neutralization. In conclusion, endogenous TNF is critical for the control of tuberculosis infection. Genetic absence or pharmacological neutralization of TNF results in uncontrolled infection, while selective neutralization might retain the desired anti-inflammatory effect but reduce the infectious risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400533     DOI: 10.1684/ecn.2007.0083

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  14 in total

Review 1.  Transcriptional control of the TNF gene.

Authors:  James V Falvo; Alla V Tsytsykova; Anne E Goldfeld
Journal:  Curr Dir Autoimmun       Date:  2010-02-18

2.  Soluble TNFRp75 regulates host protective immunity against Mycobacterium tuberculosis.

Authors:  Roanne Keeton; Nasiema Allie; Ivy Dambuza; Brian Abel; Nai-Jen Hsu; Boipelo Sebesho; Philippa Randall; Patricia Burger; Elizabeth Fick; Valerie F J Quesniaux; Bernhard Ryffel; Muazzam Jacobs
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

3.  Multifunctional T Cell Response to DosR and Rpf Antigens Is Associated with Protection in Long-Term Mycobacterium tuberculosis-Infected Individuals in Colombia.

Authors:  Leonar Arroyo; Mauricio Rojas; Kees L M C Franken; Tom H M Ottenhoff; Luis F Barrera
Journal:  Clin Vaccine Immunol       Date:  2016-10-04

Review 4.  Opening Pandora's Box: Mechanisms of Mycobacterium tuberculosis Resuscitation.

Authors:  Ashley V Veatch; Deepak Kaushal
Journal:  Trends Microbiol       Date:  2017-09-11       Impact factor: 17.079

5.  Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area.

Authors:  Hye Won Kim; Jin Kyun Park; Ji-Ae Yang; Young Im Yoon; Eun Young Lee; Yeong Wook Song; Hang Rae Kim; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2013-09-22       Impact factor: 2.980

6.  Pulmonary mycobacterial granuloma increased IL-10 production contributes to establishing a symbiotic host-microbe microenvironment.

Authors:  Christopher R Shaler; Kapilan Kugathasan; Sarah McCormick; Daniela Damjanovic; Carly Horvath; Cherrie-Lee Small; Mangalakumari Jeyanathan; Xiao Chen; Ping-Chang Yang; Zhou Xing
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

7.  Regulatory T cells modulate Th17 responses in patients with positive tuberculin skin test results.

Authors:  Subash Babu; Sajid Q Bhat; N Pavan Kumar; V Kumaraswami; Thomas B Nutman
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

8.  Histamine plays an essential regulatory role in lung inflammation and protective immunity in the acute phase of Mycobacterium tuberculosis infection.

Authors:  D Carlos; C Fremond; A Samarina; V Vasseur; I Maillet; S G Ramos; F Erard; V Quesniaux; H Ohtsu; C L Silva; L H Faccioli; B Ryffel
Journal:  Infect Immun       Date:  2009-10-12       Impact factor: 3.441

9.  IL-10 dependent suppression of type 1, type 2 and type 17 cytokines in active pulmonary tuberculosis.

Authors:  Nathella Pavan Kumar; Venugopal Gopinath; Rathinam Sridhar; Luke E Hanna; Vaithilingam V Banurekha; Mohideen S Jawahar; Thomas B Nutman; Subash Babu
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

10.  Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.

Authors:  Kerstin Walter; Julia Kokesch-Himmelreich; Axel Treu; Franziska Waldow; Doris Hillemann; Nikolas Jakobs; Ann-Kathrin Lemm; Dominik Schwudke; Andreas Römpp; Christoph Hölscher
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.